228
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate Vaccine Effectiveness

Pages 5167-5182 | Received 10 May 2022, Accepted 04 Aug 2022, Published online: 03 Sep 2022

Figures & data

Figure 1 COVID-19 breakthrough infection journey by manufacturer of COVID vaccine (A Janssen; B Pfizer-BioNTech or Moderna).

Figure 1 COVID-19 breakthrough infection journey by manufacturer of COVID vaccine (A Janssen; B Pfizer-BioNTech or Moderna).

Table 1 Characteristics at Enrollment of Study Participants*

Table 2 Number of Participants with COVID-19 Infections by Vaccination Status and Characteristics of Infection

Figure 2 Flowchart of study sample and participant counts with COVID-19 infection.

Figure 2 Flowchart of study sample and participant counts with COVID-19 infection.

Table 3 Number of Participants with COVID-19 Infections by Age Group

Table 4 Characteristics of COVID-19 Positive Participants at Enrollment *

Table 5 COVID-19 Infection Symptoms Among COVID-19 Positive Participants*

Figure 3 Percentage of COVID-19 infected participants with symptoms by vaccination status.

Figure 3 Percentage of COVID-19 infected participants with symptoms by vaccination status.

Figure 4 Number of symptoms among COVID-19 infected participants by vaccination status.

Figure 4 Number of symptoms among COVID-19 infected participants by vaccination status.

Figure 5 Number of moderate or severe symptoms among COVID-19 infected participants by vaccination status.

Figure 5 Number of moderate or severe symptoms among COVID-19 infected participants by vaccination status.

Figure 6 Percentage of hospitalized participants among COVID-19 infected by vaccination status.

Figure 6 Percentage of hospitalized participants among COVID-19 infected by vaccination status.